Artal Group S.A. Mi Nk Therapeutics, Inc. Transaction History

Artal Group S.A.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$1.1 - $2.09 $248,930 - $472,966	-226,300 Reduced 99.16%	1,916 $2,000
Q2 2023 Aug 11, 2023	SELL	$0.89 - $3.33 $54,621 - $204,368	-61,372 Reduced 21.19%	228,216 $479,000
Q4 2021 Feb 11, 2022	BUY	$4.12 - $20.03 $1.19 Million - $5.8 Million	289,588 New	289,588 $1.29 Million

912K

Ticker INKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,775,100
Market Cap $24.7M
Description
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.